Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

FOSTER CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced poster presentations on vebreltinib (APL-101) at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, Calif.

Copies of the posters will be made available on the Apollomics website following the presentation at ir.apollomicsinc.com/news-events/presentations.

Poster Presentation Details

Title:	Vebreltinib: A novel brain-penetrating MET kinase inhibitor demonstrates the mechanism of action and pharmacological anti-tumor activity in diverse patient-derived MET-dysregulated tumor models at clinically relevant drug levels
Session Category:	Experimental and Molecular Therapeutics, Molecular/Cellular Biology and Genetics
Session Title:	Kinase and Phosphatase Inhibitors 1
Section #:	25
Date and Time:	April 7, 2024, 1:30 p.m. – 5:00 p.m. PT
Title:	Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor
Session Category:	Clinical Research, Pediatric Cancer
Session Title:	Targeting Kinase and ERK Pathways
Section #:	46
Date and Time:	April 9, 2024, 1:30 p.m. – 5:00 p.m. PT

About vebreltinib (APL-101)

Vebreltinib is a potent, small molecule, orally bioavailable, brain penetrating and highly selective c-MET inhibitor. It works by inhibiting the aberrant activation of the HGF/c-MET axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies such as osimertinib. By targeting c-MET dysregulation, vebreltinib offers a potential breakthrough for many cancers driven by c-MET alterations.